Curcumin inhibits the TGF-β1-dependent differentiation of lung fibroblasts via PPARγ-driven upregulation of cathepsins B and L.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 01 2019
Historique:
received: 11 06 2018
accepted: 26 11 2018
entrez: 26 1 2019
pubmed: 27 1 2019
medline: 23 7 2020
Statut: epublish

Résumé

Pulmonary fibrosis is a progressive disease characterized by a widespread accumulation of myofibroblasts and extracellular matrix components. Growing evidences support that cysteine cathepsins, embracing cathepsin B (CatB) that affects TGF-β1-driven Smad pathway, along with their extracellular inhibitor cystatin C, participate in myofibrogenesis. Here we established that curcumin, a potent antifibrotic drug used in traditional Asian medicine, impaired the expression of both α-smooth muscle actin and mature TGF-β1 and inhibited the differentiation of human lung fibroblasts (CCD-19Lu cells). Curcumin induced a compelling upregulation of CatB and CatL. Conversely cystatin C was downregulated, which allowed the recovery of the peptidase activity of secreted cathepsins and the restoration of the proteolytic balance. Consistently, the amount of both insoluble and soluble type I collagen decreased, reaching levels similar to those observed for undifferentiated fibroblasts. The signaling pathways activated by curcumin were further examined. Curcumin triggered the expression of nuclear peroxisome proliferator-activated receptor γ (PPARγ). Contrariwise PPARγ inhibition, either by an antagonist (2-chloro-5-nitro-N-4-pyridinyl-benzamide) or by RNA silencing, restored TGF-β1-driven differentiation of curcumin-treated CCD-19Lu cells. PPARγ response element (PPRE)-like sequences were identified in the promoter regions of both CatB and CatL. Finally, we established that the transcriptional induction of CatB and CatL depends on the binding of PPARγ to PPRE sequences as a PPARγ/Retinoid X Receptor-α heterodimer.

Identifiants

pubmed: 30679571
doi: 10.1038/s41598-018-36858-3
pii: 10.1038/s41598-018-36858-3
pmc: PMC6345753
doi:

Substances chimiques

PPAR gamma 0
PPARG protein, human 0
TGFB1 protein, human 0
Transforming Growth Factor beta1 0
CTSB protein, human EC 3.4.22.1
Cathepsin B EC 3.4.22.1
CTSL protein, human EC 3.4.22.15
Cathepsin L EC 3.4.22.15
Curcumin IT942ZTH98

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

491

Références

J Clin Invest. 1999 Aug;104(4):383-9
pubmed: 10449430
EMBO J. 2001 Sep 3;20(17):4629-33
pubmed: 11532926
Chem Rev. 2002 Dec;102(12):4459-88
pubmed: 12475197
Cochrane Database Syst Rev. 2003;(3):CD002880
pubmed: 12917934
Am J Respir Cell Mol Biol. 2003 Sep;29(3 Suppl):S19-26
pubmed: 14503549
Am J Respir Cell Mol Biol. 2004 Jan;30(1):1-5
pubmed: 14512375
Am J Pathol. 2004 Jun;164(6):2203-16
pubmed: 15161653
Am J Physiol Lung Cell Mol Physiol. 2005 Jun;288(6):L1146-53
pubmed: 15734787
World J Gastroenterol. 2005 Mar 28;11(12):1747-52
pubmed: 15793857
Respir Med. 2006 Feb;100(2):340-7
pubmed: 16002271
Cardiovasc Res. 2006 Feb 15;69(3):562-73
pubmed: 16405877
Urology. 2006 Feb;67(2):440-6
pubmed: 16461119
Proc Am Thorac Soc. 2006 Jun;3(4):330-8
pubmed: 16738197
Biol Chem. 2006 Jul;387(7):863-70
pubmed: 16913835
J Cell Physiol. 2007 Jun;211(3):585-9
pubmed: 17387717
Am J Pathol. 2007 Jun;170(6):1807-16
pubmed: 17525249
J Pathol. 2007 Dec;213(4):441-52
pubmed: 17935147
Biochimie. 2008 Feb;90(2):208-26
pubmed: 17935853
J Biol Chem. 2007 Dec 21;282(51):37045-52
pubmed: 17942402
Respir Res. 2008 Jul 18;9:54
pubmed: 18638383
Nature. 2008 Nov 20;456(7220):350-6
pubmed: 19043829
Expert Opin Investig Drugs. 2009 May;18(5):585-600
pubmed: 19388876
Respir Res. 2009 Dec 24;10:127
pubmed: 20034386
Am J Physiol Lung Cell Mol Physiol. 2010 May;298(5):L616-25
pubmed: 20061443
Respir Res. 2011 May 31;12:72
pubmed: 21627832
J Biol Chem. 2011 Aug 19;286(33):28858-66
pubmed: 21700710
Hypertension. 2011 Nov;58(5):882-7
pubmed: 21931072
Biochim Biophys Acta. 2012 Jan;1824(1):68-88
pubmed: 22024571
Respir Res. 2011 Nov 29;12:154
pubmed: 22126332
Int J Biochem Cell Biol. 2012 Mar;44(3):469-74
pubmed: 22226817
J Clin Invest. 2012 Aug;122(8):2756-62
pubmed: 22850886
Lancet. 2012 Aug 18;380(9842):680-8
pubmed: 22901889
Biofactors. 2013 Jan-Feb;39(1):37-55
pubmed: 22996381
PLoS One. 2013;8(2):e57285
pubmed: 23437361
PLoS One. 2013;8(3):e58848
pubmed: 23544048
Proteomics Clin Appl. 2014 Jun;8(5-6):447-53
pubmed: 24178809
Am J Pathol. 2014 May;184(5):1429-45
pubmed: 24650561
Biochim Biophys Acta. 2014 Aug;1840(8):2560-70
pubmed: 24680817
J Biol Chem. 2014 Jun 6;289(23):16239-51
pubmed: 24790080
Biol Chem. 2015 Feb;396(2):111-30
pubmed: 25178906
Dig Dis Sci. 2015 Jun;60(6):1554-64
pubmed: 25532502
Matrix Biol. 2015 May-Jul;44-46:167-74
pubmed: 25686691
Biochem Biophys Res Commun. 2015 May 1;460(2):250-4
pubmed: 25778864
Biol Chem. 2015 Aug;396(8):867-82
pubmed: 25872877
Mol Cell Proteomics. 2015 Aug;14(8):2213-28
pubmed: 26081835
World J Methodol. 2016 Mar 26;6(1):112-7
pubmed: 27019802
Brain Res. 2016 Sep 1;1646:580-588
pubmed: 27373979
Br J Pharmacol. 2017 Jun;174(11):1325-1348
pubmed: 27638428
Respir Res. 2016 Sep 22;17(1):118
pubmed: 27658724
Front Pharmacol. 2016 Nov 08;7:419
pubmed: 27877129
Pharmacol Res. 2017 Jan;115:133-148
pubmed: 27888157
Eur Respir J. 2017 Feb 8;49(2):
pubmed: 28179435
Biomed Res Int. 2017;2017:2418671
pubmed: 28546962
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):65-73
pubmed: 28561324
Clin Transl Gastroenterol. 2017 Jun 15;8(6):e99
pubmed: 28617446
Matrix Biol. 2018 Jan;65:30-44
pubmed: 28634008
Nat Rev Dis Primers. 2017 Oct 20;3:17074
pubmed: 29052582
Nucleic Acids Res. 2018 Jan 4;46(D1):D624-D632
pubmed: 29145643
Eur Respir Rev. 2018 Jan 24;27(147):null
pubmed: 29367408
Matrix Biol. 2018 Feb 1;:null
pubmed: 29409929
Matrix Biol. 2018 Aug;68-69:122-149
pubmed: 29458139
Matrix Biol. 2018 Aug;68-69:382-403
pubmed: 29518524
Mol Cell Biol. 1988 May;8(5):2229-32
pubmed: 3164441
Int Rev Immunol. 1995;12(2-4):177-85
pubmed: 7650420
N Engl J Med. 1994 Nov 10;331(19):1286-92
pubmed: 7935686
J Clin Invest. 1997 Aug 15;100(4):768-76
pubmed: 9259574
Biochem Biophys Res Commun. 1998 Mar 27;244(3):671-7
pubmed: 9535723
Annu Rev Biochem. 1998;67:753-91
pubmed: 9759503

Auteurs

Ahlame Saidi (A)

Université de Tours, Tours, France.
INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Equipe «Mécanismes Protéolytiques dans l'Inflammation», Tours, France.

Mariana Kasabova (M)

Université de Tours, Tours, France.
INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Equipe «Mécanismes Protéolytiques dans l'Inflammation», Tours, France.
Pharmaceutical Product Development, Sofia, Bulgaria.

Lise Vanderlynden (L)

Université de Tours, Tours, France.
INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Equipe «Mécanismes Protéolytiques dans l'Inflammation», Tours, France.

Mylène Wartenberg (M)

Université de Tours, Tours, France.
INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Equipe «Mécanismes Protéolytiques dans l'Inflammation», Tours, France.

Ghania Hounana Kara-Ali (GH)

Université de Tours, Tours, France.
INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Equipe «Mécanismes Protéolytiques dans l'Inflammation», Tours, France.

Daniel Marc (D)

Université de Tours, Tours, France.
INRA, UMR 1282, Infectiologie et Santé publique (ISP), Centre INRA Val de Loire, Nouzilly, France.

Fabien Lecaille (F)

Université de Tours, Tours, France.
INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Equipe «Mécanismes Protéolytiques dans l'Inflammation», Tours, France.

Gilles Lalmanach (G)

Université de Tours, Tours, France. gilles.lalmanach@univ-tours.fr.
INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Equipe «Mécanismes Protéolytiques dans l'Inflammation», Tours, France. gilles.lalmanach@univ-tours.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH